anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Another product containing articaine with epinephrine 1:100,000 was studied in three randomized, double-blind, active-controlled trials to evaluate the effectiveness of articaine containing epinephrine 1:100,000 as a dental anesthetic. Patients ranging in age from 4 years to over 65 years old underwent simple dental procedures such as single uncomplicated extractions, routine operative procedures, single apical resections, and single crown procedures, or complex dental procedures such as multiple extractions, multiple crowns and/or bridge procedures, multiple apical resections, alveolectomies, muco-gingival operations, and other surgical procedures on the bone. Articaine containing epinephrine 1:100,000 was administered by intraoral submucosal infiltration for these dental procedures.

Efficacy was measured immediately following the procedure by having the patient and investigator rate the patient’s procedural pain using a 10 cm visual analog scale (VAS), in which a score of zero represented no pain and a score of 10 represented the worst pain imaginable. Mean patient and investigator VAS pain scores were 0.3 cm-0.4 cm for simple procedures and 0.5 cm-0.6 cm for complex procedures.

Articaine with epinephrine 1:100,000 was also studied compared to articaine with epinephrine 1:200,000 in four randomized, double-blind, active controlled trials. The first two studies used electric pulp testers (EPT) to evaluate the success rate (maximum EPT value within 10 minutes), onset, and duration of articaine containing epinephrine 1:100,000 versus articaine containing epinephrine 1:200,000 and articaine solution without epinephrine in healthy adults between 18 and 65 years old. Results indicated that the anesthetic characteristics of the 1:100,000 and 1:200,000 formulations were not significantly different.

A third study compared the difference in visualization of the surgical field after administration of articaine containing 1:100,000 epinephrine versus articaine containing 1:200,000 epinephrine during bilateral maxillary periodontal surgeries in patients ranging from 21 to 65 years old. Articaine containing 1:100,000 epinephrine provided better visualization of the surgical field and less blood loss during the procedures. In a fourth study, designed to assess and compare cardiovascular safety, when the maximum dose of each formulation was administered, no clinically relevant differences in blood pressure or heart rate between formulations were observed.
The present invention is directed to polymorphs of benfotiamine, their methods of preparation and the use thereof. The crystalline forms of benfotiamine are crystalline forms A, B, C, D and E, and can be distinguished by their respective patterns of X-ray powder diffraction, DSC, infrared spectroscopy, Raman spectroscopy, and preparation methods. The invention is also directed to the use of the above-mentioned polymorphs of benfotiamine for treating Vitamin B1 deficiency, metabolism-related disorders, psychiatric diseases and disorders, diabetes complications, or neurodegenerative diseases. The different crystalline forms of benfotiamine are obtained using different synthetic routes and solvent ratios. The crystalline polymorphs are substantially pure. The invention not only provides new crystalline forms of benfotiamine, but also solvates thereof, especially hydrates.
Vietnam War Theater Veterans are defined for this protocol as those who served in the U.S. Armed Forces on the ground, in the air, or on the inland waters of Vietnam, Cambodia, and/or Laos between February 28, 1961 and May 7, 1975, inclusive. The investigators based this definition on legal dates of service set forth in 38 Code of Federal Regulations (CFR) 3.2 - Periods of war, but broadened the definition of sites of military service that constituted war zones based on written historical accounts and input from Vietnam Veterans.
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous and multisystemic disease with progressive increasing morbidity and mortality. Chronic obstructive pulmonary disease (COPD) is a deteriorating respiratory disease with some extrapulmonary effects that contribute to disease severity in patient. The etiology, in general, involves exposure to external noxious particles or gases. In the Western world this is particularly a result of (cigarette) smoking and in the non-Western world it is mainly a result of indoor cooking. COPD pathology is driven by chronic inflammation, which continues to be observed after stopping smoking, even after ⩾1 year. The combination of the exposure and inflammation leads to lung tissue damage, resulting in remodeling of the lung.Global Burden of Disease programme in 2010 identified chronic obstructive pulmonary disease (COPD) as the third leading cause of death worldwide up from 4th in 1990. This high mortality due to COPD is caused due to smoking and rapidly aging population. China alone contributed to about one-third (0.9million/year) of all deaths from COPD worldwide. Within China, the prevalence of COPD varies substantially by region and death rates attributed to COPD are twofold greater in South-West compared with North-East regions for reasons that are not fully understood.

Physical activity in terms of body movements, walking time and standing time has been shown to be reduced in patients with severe COPD. However, it is currently unknown at which clinical stage of the disease limitations of physical activity are first displayed. Furthermore, the relationships between physical activity and clinical characteristics reflecting the disease severity, such as the degree of airway obstruction, distance walked in 6 min, self-reported grade of dyspnea and clinical stages of COPD, need to be investigated as, to date, data are inconclusive or have never been evaluated. For example, some studies have found substantial correlations between airway obstruction and physical activity, while others found no or only loose relationships. Previous studies indicate that the 6-min walking distance (6MWD) might best reflect physical activity, while a recent study found airway obstruction to correlate with physical activity better than 6MWD.
This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. <??>It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. <??>Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. <??>Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.
Use of mimosa extract for the preparation of a cosmetic and/or dermatological composition for topical application, to fight against signs of skin aging. An independent claim is included for a cosmetic process to combat the signs of skin aging, comprising applying the composition containing the mimosa extract. ACTIVITY : Nootropic; Dermatological. MECHANISM OF ACTION : Metallo-proteinase inhibitor. The effect of the mimosa extract to inhibit the metallo-proteinase was tested in co-culture of reconstituted epidermis/human fibroblasts using enzyme-linked-immunosorbent serologic assay. The result showed that the mimosa decreased the metallo-proteinase expression of 20%, 28%, and 41%, at a concentration of 0.2%, 0.5% and 1% respectively.
The present study was conducted to assess the impact of non-encapsulated, air-dried microencapsulated, and lyophilized microencapsulated probiotics in indigenous cattle calves (Bos indicus). Twenty-four (5-7 days old) indigenous cattle calves were selected and assigned into four groups, with six calves in each as follows: control (CON), fed milk and basal diet alone, and treatment groups supplemented with non-encapsulated (NEC), air-dried microencapsulated (AEC) and lyophilized microencapsulated (LEC) probiotic L. reuteri SW23 at 108 CFU/head/day in skim milk as a carrier provided for 60 days. The animals were divided into four groups, adopting a complete randomized design, and the effects were considered significant at p ≤ 0.05. Probiotics supplementation increased (p < 0.05) body weight gain (kg), average daily gain, and structural growth measurements in calves of all treatment groups. Dry matter intake (g/d), feed conversion efficiency, and fecal counts of Lactobacilli and Bifidobacteria were also increased in the treatment groups compared to CON. The fecal consistency index was highest in CON (0.70 ± 0.03), followed by NEC (0.68 ± 0.01), AEC (0.66 ± 0.02), and LEC (0.65 ± 0.02). Fecal pH and ammonia levels were reduced (p < 0.05) in the probiotic-fed groups compared to CON, with a concomitant increase in fecal lactate, acetate, and propionate levels. In addition, cell-mediated and humoral immunity were significantly increased in supplemented groups as compared to CON. Thus, it can be concluded that supplementation of the probiotics in microencapsulated/non-encapsulated forms to neonatal calves had a variety of positive effects on their health, including better performance, improved gut health, and a lower fecal consistency index. Moreover, among all supplemented groups, the lyophilized microencapsulated group outperformed air-dried microencapsulated and non-microencapsulated groups in terms of ADG, DMI, and gut health.
PURPOSE:To efficiently collect the subject human tumor necrosis factor naturally produced in the human body from blood plasma components by culturing a collected whole human blood in the presence of an anticoagulant and a stimulant and subsequently purifying the whole blood. CONSTITUTION:A necessary and sufficient amount of an anticoagulant such as sodium tartrate or heparin is rapidly admixed with a collected human whole blood. The blood is transferred to a suitable culture vessel without more treatment and incubation is started in a heat incubator at about 37 deg.C. If a various concentration of a stimulant for lymphocyte and macrophage is added at the start of the incubation, the amount of the human tumor necrosis factor(TNF) produced and generated in the culture remarkably increases. After completion of incubation, cell components are separated from liquid components using the centrifugation method, etc., to collect the liquid components. The above- obtained cultured material also may be stored as a TNF-containing blood plasma without more treatment.
Rationale: The combination of the chemotherapy drugs paclitaxel and carboplatin is one of the most common combination regimens used in clinical practice for cancer. These agents are used for a variety of cancers. The current study builds on previous research about treatment schedules for administering these agents to reduce toxicity and optimize efficacy. The phase I and II portions of the current study combine paclitaxel and carboplatin with capecitabine in patients. Researchers are seeking to identify the highest dose of capecitabine and paclitaxel in combination with carboplatin for this patient population, as well as to gather information about preliminary efficacy.

Purpose: The phase I portion of this study will evaluate the maximum tolerated dose of capecitabine and paclitaxel in combination with carboplatin for patients. The phase II portion of this study will assess the objective response rate in patients using the same treatment combination. Toxicities will be closely measured in both phases of the study.

Treatment: Patients in this study will be given capecitabine, carboplatin, and paclitaxel. Capecitabine will be given through oral pills. Carboplatin and paclitaxel will be given through intravenous infusions. Treatment drugs will be given on a four-week cycle. Carboplatin will be administered on day 1, paclitaxel weekly for the first 3 weeks, and capecitabine twice daily on days 8 through 21 of each cycle. No treatments will be given during the fourth week of each treatment cycle. During the phase I portion of the study, patients may receive different doses of capecitabine and paclitaxel since the purpose is to identify the maximum tolerated dose of each drug in combination with carboplatin. Once the maximum tolerated dose of these agents is identified during phase I, the phase II portion of the study will begin. Treatments will be discontinued due to disease growth or unacceptable side effects. Several tests and exams will be given throughout the study to closely monitor patients.
A gas releasable elastic structure includes a cap body, a ring-shaped flange, a motion pillar, and a conductor. The cap body has a first opening and a second opening that is opposite the first opening and smaller than the first opening. The ring-shaped flange connects an edge around the first opening of the cap body. The motion pillar is disposed in the cap body and has a through hole, an upper surface and a lower surface opposite the upper surface. The upper surface connects an inner wall of the second opening. The lower surface is opposite the first opening. The through hole extends from the lower surface to the upper surface and connects the second opening. The conductor is disposed on the lower surface, and has a breach and an indent. The breach corresponds to the through hole and connects the through hole and the indent. As the first opening is closed, the gas inside the cap body is dissipated to the exterior of the cap body via the indent, breach, through hole and second opening.
Cross-sectional prospective analysis of clinical efectiveness of a diabetes educational program to improve intermittently continuous glucose monitoring (iCGM) adherence in adult type 1 diabetes (T1D) patients. Glycometric data obtained through deidentified downloads from isCGM´s webpage. Primary outcome was time in range (TIR) 3.0-10 mmol/L (70-180 mg/d) change after the heatwave. Data analysis is conducted using SPSS (Chicago, IL) statistics software. Results are presented as mean ± SD values or percentages. A paired Student's t-test or a Wilcoxon signed-rank test were used for the analysis of differences. Comparisons between proportions were analyzed using a chi-squared test. A P value \< 0.05 was considered statistically significant. The protocol was approved by the reference Castilla-La Mancha Public Health Institute Ethic Committee (C-558).
Pain is one of the most common and debilitating symptoms in patients with advanced cancer and opioids are the main stay of treatment for cancer pain. However, initiation of opioid-therapy is frequently hindered by OINV. OINV is a highly distressing symptom and can affect medication compliance, enteral absorption, and quality of life.This Phase II feasibility study is conducted to assess the feasibility of the prophylactic antiemetic treatment of OINV with palonosetron in comparison to placebo. The objective is to investigate the feasibility of patient recruitment and implementation of the study design as well as to obtain an initial estimate of the antiemetic efficacy and safety of prophylactic treatment of OINV with palonosetron compared to placebo. A total of 30 palliative patients starting an opioid-therapy (WHO II \& III) for cancer pain will be randomly assigned to receive either a single dose of placebo or palonosetron. Safety and efficiency assessment are based on patient reports regarding OINV, pain and safety parameters during the following 6 days.
Participants in Russia and Brasil will receive 80 mg Simvastatin + niacin. All other participants will receive 80 mg Atorvastatin + niacin.
Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and "Masako" maneuver, the first two with bolus administration, if possible. The control group will attend this training for 45 minutes, receiving verbal feedback from the speech and language therapist.
Patients will receive a 15-day lead-in of anti-OX40 antibody PF-04518600, followed by anti-OX40 antibody PF-04518600 IV over 60 minutes and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
OBJECTIVES: Stimuli that are separated by a short window of space or time, known as spatial and temporal binding windows (SBW/TBWs), may be perceived as separate. Widened TBWs are evidenced in schizophrenia, although it is unclear if the SBW is similarly affected. The current study aimed to assess if dexamphetamine (DEX) may increase SBWs in a multimodal visuo-tactile illusion, potentially validating usefulness as an experimental model for multimodal visuo-tactile hallucinations in schizophrenia, and to examine a possible association between altered binding windows (BWs) and working memory (WM) suggested by previous research.
METHODS: A placebo-controlled, double-blinded, and counter-balanced crossover design was employed. Permuted block randomisation was used for drug order. Healthy participants received DEX (0.45 mg/kg, PO, b.i.d.) or placebo (glucose powder) in capsules. The Rubber Hand Illusion (RHI) and Wechsler Adult Intelligence Scale Spatial Span was employed to determine whether DEX would alter SBWs and WM, respectively. Schizotypy was assessed with a variety of psychological scales.
RESULTS: Most participants did not experience the RHI even under normal circumstances. Bi-directional and multimodal effects of DEX on individual SBWs and schizotypy were observed, but not on WM.
CONCLUSIONS: Bidirectional multimodal effects of DEX on the RHI and SBWs were observed in individuals, although not associated with alterations in WM.
STUDY OBJECTIVES: Fever following immunizations is a common presenting chiefcomplaint among infants. The 2021 American Academy of Pediatrics (AAP) febrile infant clinical practice guidelines exclude recently immunized (RI) infants. This is a challenge for clinicians in the management of the febrile RI young infant. The objective of this study was to assess the prevalence of SBI in RI febrile young infants between 6 and 12 weeks of age.
METHODS: This was a retrospective chart review of infants 6-12 weeks who presented with a fever ≥38 °C to two U.S. military academic Emergency Departments over a four-year period. Infants were considered recently immunized (RI) if they had received immunizations in the preceding 72 h prior to evaluation and not recently immunized (NRI) if they had not received immunizations during this time period. The primary outcome was prevalence of serious bacterial infection (SBI) further delineated into invasive-bacterial infection (IBI) and non-invasive bacterial infection (non-IBI) based on culture and/or radiograph reports.
RESULTS: Of the 508 febrile infants identified, 114 had received recent immunizations in the preceding 72 h. The overall prevalence of SBI was 11.4% (95% CI = 8.9-14.6) in our study population. The prevalence of SBI in NRI infants was 13.7% (95% CI = 10.6-17.6) compared to 3.5% (95% CI = 1.1-9.3) in RI infants. The relative risk of SBI in the setting of recent immunizations was 0.3 (95% CI = 0.1-0.7). There were no cases of invasive-bacterial infections (IBI) in the RI group with all but one of the SBI being urinary tract infections (UTI). The single non-UTI was a case of pneumonia in an infant who presented with respiratory symptoms within 24 h of immunizations.
CONCLUSION: The risk of IBI (meningitis or bacteremia) in RI infants aged 6 to 12 weeks is low. Non-IBI within the first 24 h following immunization was significantly lower than in febrile NRI infants. UTIs remain a risk in the RI population and investigation with urinalysis and urine culture should be encouraged. Shared decision making with families guide a less invasive approach to the care of these children. Future research utilizing a large prospective multi-center data registry would aid in further defining the risk of both IBI and non-IBI among RI infants.
Participants receive dose-matched placebo to MK-3281 orally BID for 7 or 10 consecutive days depending on randomization. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
PROBLEM TO BE SOLVED: To obtain a medicinal composition which is excellent in adhesion are retention without tackiness of the medicine by formulating a specific powder such as silica to a water-repellent polymer as a base. SOLUTION: This medicinal composition is prepared by formulating a medicinal component to a base material comprising (A) a volatile oil component, preferably in an amount of 10-60wt.%, (B) a water-repellent polymer soluble in the oil component, preferably in an amount of 5-35%, (C) a non-volatile oil component compatible with the above oil component in an amount of 5-40% and (D) a powder (silica is particularly suitable), preferably in an amount of 1-25wt.%. The whole surface area of the powder included in one gram of the composition is adjusted to 1-25m<2> . The powder is preferably titanium mica in addition to silica. The volatile oil is silicone oil and the water-repellent polymer is preferably a silicone resin. The weight ratio of the water-repellent polymer to the non-volatile oil is preferably 1/2-2/1.  This composition is excellent in retention of the medicine to sufficiently manifest its medicinal effect.
Commensal bacteria that breach endothelial barrier has been reported to induce low grade chronic inflammation producing disease symptoms in major peripheral tissues. In this study, we investigated the role of genetically modified cellular invasive form of commensal E. coli K12 (SK3842) in cognitive impairment. Low-grade systemic infection model was developed using recurring peripheral inoculation of live bacteria in Wistar rats. To examine memory parameters, Novel object recognition test and Radial arm maze test were performed. Differential protein expression profiling of rat hippocampus was carried out using LC-MS/MS and subsequently quantified using SWATH. HBA1/2, NEFH, PFN1 and ATP5d were chosen for validation using quantitative RT-PCR. Results showed drastic decline in Recognition memory of the SK3842 infected rats. Reference and Working Memory of the infected group were also significantly reduced in comparison to control group. Proteome analysis using LC-MS/MS coupled with SWATH revealed differential expression of key proteins that are crucial for the maintenance of various neurological functions. Moreover, expression of NEFH and PFN1transcripts were found to be in line with the proteomics data. Protein interaction network of these validated proteins generated by STRING database converged to RhoA protein. Thus, the present study establishes an association between peripheral infection of a hippocampal protein network dysregulation and overall memory decline.
Pelvic organ prolapsed (POP) is an important health issue for women all over the world, with cystocele being the commonest type of POP. The side effects related to cystocele include voiding dysfunction, urinary retention, urinary tract infection, hydroureter, or hydronephrosis. The management for cystocele can be classified as non-surgical and surgical methods. Non-surgical methods comprise pelvic floor muscle exercise and vaginal pessaries, while surgical methods can be divided as conventional operations and operations applying mesh augmentation. Conventional surgeries for cystocele such as anterior colporrhapy have high surgical failure rates and complications including vaginal shortening or vaginal stenosis. Operations applying mesh augmentation are becoming the mainstream in the surgeries for cystocle. The Perigee System (American Medical Systems, Minnetonka, MN, USA), which has been approved by American FDA and Taiwan DOH in treating female cystocele, have promising short-term surgical outcomes. However, long-term reports incorporating both functional and morphological outcomes are lacking in the literatures. This study aimed to evaluate primarily the functional outcomes and secondly the morphological outcomes for women who had received standard managements for cystocele at mediate-term follow-up.